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HAS THE EPIDEMIOLOGY OF NOSOCOMIAL
CANDIDEMIA CHANGED? 
Laura Puzniak, PhD; Steven Teutsch, MD; William Powderly, MD; Louis Polish, MD
Since early reports documenting the importance of
yeast as a cause of nosocomial infections, the role of fun-
gal organisms as a cause of infections among hospitalized
patients has increased substantially. Data from the
National Nosocomial Infections Surveillance System for
the 10-year period from 1980 to 1990 documented an
increase in the incidence of all nosocomial fungal infec-
tions from 2.0 to 3.8 infections per 1,000 patients dis-
charged, with the incidence of nosocomial fungemia
increasing from 1.0 to 4.9 infections per 10,000 dis-
charges.1 Candida species accounted for approximately
85% of the nosocomial fungal infections.1 Recent data from
the Surveillance and Control of Pathogens of
Epidemiologic Importance (SCOPE) project showed that
Candida species were the fourth most common cause of
nosocomial bloodstream infections, accounting for
approximately 8% of the total.2 C. albicans has historically
been the most frequently isolated species, accounting for
approximately 60% to 70% of the infections; however,
recent studies have documented an increase in the pro-
portion of infections due to non-albicans species.1-11
Previous studies have suggested several risk factors for
the acquisition of a nosocomial candidal bloodstream
infection.2 These data are somewhat limited by the fact
that many of the epidemiologic studies focused on specif-
ic patient populations, were observational in nature, and
were conducted prior to the era of increased use of
azoles.2,12-18
A retrospective case series of 106 patients with can-
didemia performed at our institution from September 1,
1988, to September 1, 1989, documented similar risk fac-
tors.19 Although much is known about the epidemiology
of candidemia, few recent case–control studies have been
performed among a general hospitalized patient popula-
tion. To assess changes in the epidemiology of can-
didemia since azoles have become widely used, a
case–control study was performed among all hospitalized
patients with candidemia during 2000. 
METHODS
Participants
Barnes–Jewish Hospital is a 1,287-bed, tertiary-care
center affiliated with Washington University School of
Medicine, St. Louis, Missouri. All patients admitted to
Barnes–Jewish Hospital between January 1 and December
31, 2000, with at least one blood culture positive for
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OBJECTIVE: To assess changes in the epidemiology of
nosocomial candidemia in the post-fluconazole era among hospi-
talized patients using a case–control study design.
DESIGN: Candidemia case-patients were matched 1:1 on
diagnosis, age, and length of stay with control-patients. Conditional
logistic regression was used to determine predictors and out-
comes of candidemia. Treatment regimens and compliance with
national practice guidelines were compared among case-patients.
SETTING: Barnes–Jewish Hospital, a 1,278-bed, tertiary-
care center affiliated with Washington University School of
Medicine, St. Louis, Missouri.
PARTICIPANTS: Patients admitted from January 1 to
December 31, 2000. Case-patients were identified through the
hospital microbiological surveillance system and matched with
control-patients. 
RESULTS: Predictors of candidemia included Hickman
catheters (odds ratio [OR], 9.53; 95% confidence interval [CI95],
1.34 to 68.01), gastric acid suppressants (OR, 6.38; CI95, 2.33 to
17.43), nasogastric tubes (OR, 3.69; CI95, 1.27 to 10.78), antibi-
otics (OR, 1.46; CI95, 1.15 to 1.86), and admission to the intensive
care unit (OR, 6.40; CI95, 2.12 to 19.31). The crude case-fatality
rate was 40%. Seventeen (15%) of the case-patients received the
recommended treatment regimen according to recently pub-
lished practice guidelines.
CONCLUSIONS: The epidemiology of candidemia has
changed little at our hospital during the past decade and remains
a significant cause of mortality. Further studies on the benefits of
preventive therapy will be essential to improve the outcome of
this infection (Infect Control Hosp Epidemiol 2004;25:628-633).
ABSTRACT
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Candida species were included in the study. We defined a
patient with nosocomial candidemia as any patient with at
least one blood culture positive for Candida species that
was performed at least 48 hours after admission. Case-
patients were identified through our microbiological sur-
veillance mechanism. Control-patients were selected from
all admissions to Barnes–Jewish Hospital during this same
period. This study was approved by the Human Studies
Committee at Washington University School of Medicine. 
Design
A 1:1 matched case–control study design was used
to determine the risk factors associated with Candida
bloodstream infections. A control-patient could not have
any evidence of Candida infection during the hospitaliza-
tion period studied. Matching of case-patients and control-
patients was based on the following criteria: the principal
diagnosis of the case as identified by the International
Classification of Diseases, 9th revision, Clinical
Modification code; age within 10 years; and length of hos-
pitalization. The length of stay in the hospital was calcu-
lated from the date of hospital admission until the date of
discharge for control-patients and from the date of hospi-
tal admission until the date of the first blood culture posi-
tive for Candida for case-patients. If a control-patient
could not be found to match the case-patient on principal
diagnosis, secondary diagnoses were considered. The
secondary diagnoses were used only if the primary diag-
nosis was extremely rare and the secondary diagnoses
were clinically similar to the principal diagnosis. 
Control-patients meeting the matching criteria were
identified from hospital admissions from January 1 to
December 31, 2000. Matching control-patients were ran-
domly selected for case-patients using the random digit
generator (Rand Corp., Santa Monica, CA). 
Risk Factors
Data for case-patients and control-patients were
abstracted from electronic hospital records, the medical
informatics system, and medical chart review. Demographic
data included age, race (white, black, or other), and gender.
Data were collected regarding the patient’s hospital stay
including length of stay, intensive care unit (ICU) admission,
unit of admission, and previous admissions.
Severity of illness was assessed using the Acute
Physiology and Chronic Health Evaluation (APACHE) II
score.20 APACHE II scores were calculated for case-
patients using the worst values obtained 24 hours prior to
the identification of a culture positive for Candida.
APACHE II scores were calculated for control-patients
using the worst values obtained within the first 48 hours
of hospital admission. If a patient had missing APACHE
values, the mean value from the cases was used for case-
patients and the mean value from the controls was used
for control-patients.
Various underlying medical illnesses were assessed
as dichotomous variables including diabetes mellitus,
insulin dependence, chronic obstructive pulmonary dis-
ease, solid organ tumor, hematologic malignancy, coro-
nary artery disease, congestive heart failure, asthma,
end-stage liver disease, cirrhosis and pancreatitis, human
immunodeficiency virus, acquired immunodeficiency syn-
drome, and cytomegalovirus. In addition, data were col-
lected regarding the receipt of a bone marrow or stem cell
transplant including the type of transplant, receipt of total
body irradiation, receipt of cyclophosphamide, and pro-
phylaxis for veno-occlusive disease of the liver. Data
regarding previous surgeries within a 6-month period of
hospital admission were collected including type of
surgery, surgical complications, and returns to surgery.
Nosocomial manipulations included type of central
venous catheter (eg, Hohn, Hickman, Quentin [Kendall,
Mansfield, MA], peripherally inserted central catheters, or
Swan-Ganz), nasogastric feeding tube, gastrostomy tube,
nasogastric tube, endotracheal tube, tracheostomy, Foley
catheter, chest tube, and surgical drains. Dichotomous vari-
ables were created regarding hemodialysis and the receipt
of a transfusion of red blood cells, whole blood, or platelets.
Pharmacologic data were collected including the receipt
and duration of antibiotics, adrenocortical steroids,
immunosuppressants, chemotherapy, and gastric acid sup-
pressants. Compliance with the practice guidelines of the
Infectious Diseases Society of America for the treatment of
candidemia was assessed among the case-patients.
The cost of hospitalization for each patient was
obtained from the cost accounting database of Barnes–
Jewish Hospital. Mean costs of hospitalization and ranges
were compared between case-patients and control-patients.
Statistical Analyses
Demographics, nosocomial exposures, severity of
illness, and underlying medical illness variables were
compared for case-patients and matched control-patients
using the chi-square test for categorical variables and the
t test for continuous variables. Conditional logistic regres-
sion for matched data was performed for multivariate
analyses with SPSS software (version 10.0; SPSS, Inc.,
Chicago, IL). Significant risk factors (P < .05) were con-
sidered in the multivariate analyses. Interactions between
all main effects were assessed in each model. Regression
diagnostics were used to determine any outlying or influ-




During the study period, 113 patients with can-
didemia were identified. C. albicans was the most com-
mon isolate and accounted for 64 (56%) of the infections.
C. parapsilosis (18; 16%), C. glabrata (17; 15%), C. tropi-
calis (14; 12%), and C. krusei (2; 2%) were identified among
the remainder of case-patients. 
Twenty-six (23%) of the patients with a blood cul-
ture positive for Candida on admission were excluded
from the matched case–control analysis of patients with
nosocomial candidemia. There were 57 patients with can-
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TABLE 1
RISK FACTORS FOR CANDIDEMIA
All Species
No. of Case- No. of Control-
Factor Patients (%)* Patients (%)* OR CI95
Previous admission 35 (46.7) 31 (41.3) 1.24 0.65–2.37
APACHE II score
0% to 25% mortality 37 (49.3) 59 (78.7) 1.00
26% to 55% mortality 21 (28.0) 14 (18.7) 2.08 0.92–4.66
 56% mortality 7 (9.3) 2 (2.7) 3.73 0.72–19.27
Concomitant bloodstream infection 35 (46.7) 31 (41.3) 1.24 0.65–2.37
Medical condition
Diabetes mellitus 15 (20.0) 21 (28.0) 0.64 0.30–1.37
Insulin dependent 7 (9.3) 17 (22.7) 0.35 0.14–0.91
COPD 8 (10.7) 8 (10.7) 1.00 0.36–2.82
Asthma 3 (4.0) 3 (4.0) 1.00 0.20–5.12
ESLD 3 (4.0) 1 (1.3) 3.08 0.31–30.34
Cirrhosis 1 (1.3) 4 (5.3) 0.24 0.03–2.20
Pancreatitis 4 (5.3) 3 (4.0) 1.35 0.29–6.26
CAD 21 (28.0) 8 (10.7) 3.26 1.34–7.93†
CHF 19 (25.3) 8 (10.7) 2.84 1.16–6.98†
Hematologic malignancy 14 (18.7) 14 (18.7) 1.00 0.44–2.27
Nosocomial manipulation
ICU admission 41 (54.7) 8 (10.7) 10.10 4.26–23.93†
Neutropenia 6 (8.0) 4 (5.3) 1.54 0.42–5.7
Central venous catheter 55 (73.3) 34 (45.3) 3.32 1.67–6.58†
Hohn 28 (37.3) 22 (29.3) 1.44 0.73–2.84
Hickman 13 (17.3) 2 (2.7) 7.65 1.66–35.23†
Quentin‡ 4 (5.3) 3 (4.0) 1.35 0.29–6.26
PICC 3 (4.0) 8 (10.7) 0.35 0.09–1.37
Swan-Ganz 14 (18.7) 6 (8.0) 2.64 0.96–7.29
Feeding tube 34 (45.3) 14 (18.7) 3.61 1.73–7.56†
Nasogastric tube 43 (57.3) 12 (16.0) 7.06 3.27–15.21†
Gastrostomy 10 (13.3) 11 (14.7) 0.90 0.36–2.25
Endotracheal tube 43 (57.3) 17 (22.7) 4.56 2.26–9.31†
Foley catheter 55 (73.3) 35 (46.7) 3.14 1.59–6.23†
RBC transfusion 42 (56.0) 38 (50.7) 1.24 0.65–2.36
Platelet transfusion 20 (26.7) 9 (12.0) 2.67 1.12–6.33†
Drug therapy
Adrenal corticosteroids 37 (49.3) 11 (14.7) 5.67 2.59–12.40†
Antibiotics
None 5 (6.7) 30 (40.0) 1.00
1 to 3 29 (38.7) 30 (40.0) 5.80 1.98–16.99†
4 or more 41 (54.7) 15 (20.0) 6.81 3.06–15.14†
Immunosuppressants 17 (22.7) 8 (10.7) 2.46 0.99–6.10
Gastric suppressants 37 (49.3) 13 (17.3) 4.64 2.19–9.83†
Surgery 
Previous surgery 40 (53.3) 32 (42.7) 1.54 0.81–2.93
Neurosurgery 2 (2.7) 0 1.54 0.60–3.98
Cardiac 10 (13.3) 6 (8.0) 1.77 0.61–5.15
Thoracic 10 (13.3) 5 (6.7) 2.15 0.70–6.64
Gastrointestinal 11 (14.7) 7 (9.3) 1.67 0.61–4.57
Obstetrics/gynecology 3 (4.0) 4 (5.3) 0.74 0.16–3.42
Urology 3 (4.0) 0
Orthopedic 4 (5.3) 8 (10.7) 0.47 0.14–1.64
ENT 1 (1.3) 2 (2.7) 0.49 0.04–5.56
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didemia (66%) who had another site positive for a Candida
species or yeast (not further identified). 
Control-Patients
There was a match on principal or secondary diag-
nosis, age, and length of stay for 75 (86%) of 87 case-
patients. Control-patients were randomly matched on all
criteria (principal diagnosis, age, and length of stay) with
64 (74%) of 87 case-patients. The secondary diagnosis was
used for patients who had disseminated candidemia as a
principal diagnosis or whose principal diagnoses were
rare. 
Analysis: Match Criteria = Principal Diagnosis
+ Age + Length of Stay
Demographic characteristics were not significantly
dif ferent between case-patients and control-patients.
However, there were slight differences in underlying
medical histories between case-patients and control-
patients. Case-patients were more likely than control-
patients to have coronary artery disease (21 [28.0%] vs 8
[10.7%], respectively; P < .01) and congestive heart failure
(19 [25.3%] vs 8 [10.7%], respectively; P < .01). Surgical
histories within the past 6 months were not significantly
dif ferent between case-patients and control-patients.
Case-patients had more severe illness using the APACHE
II score compared with control-patients (19.28 vs 15.60;
P < .01) and the percentage of case-patients with ICU
admissions was significantly higher than the percentage
of control-patients (41 [54.7%] vs 8 [10.7%]; P < .01). There
were 29 (38.7%) deaths among case-patients compared
with 3 (4.0%) deaths among control-patients (P < .01)
(Table 1). The average cost of hospitalization for case-
patients was $77,434 compared with $33,383 for control-
patients (range, $2,212 to $197,184; P < .01). 
Nosocomial risk factors significantly more common
in case-patients are listed in Table 1 and included the pres-
ence of a central venous catheter (particularly a Hickman
catheter), nasogastric tube, endotracheal tube, and Foley
catheter. Other risk factors identified in univariate analysis
to be significantly more common among case-patients
included receipt of a platelet transfusion, corticosteroids,
gastric acid suppressants, and antibiotics. Most (93.4%) of
the case-patients received at least one antibiotic compared
with 60.0% of the control-patients. Case-patients were also
more likely to receive more than 4 antibiotics (54.7%)
compared with control-patients (20.0%). 
With the use of multivariate analyses, risk factors
identified as predictors of candidemia included presence
of a Hickman catheter (adjusted odds ratio, 9.53; 95% con-
fidence interval [CI95], 1.34 to 68.01), receipt of a gastric
acid suppressant (adjusted OR, 6.38; CI95, 2.33 to 17.43),
ICU admission (adjusted OR, 6.40; CI95, 2.12 to 19.31),
presence of a nasogastric tube (adjusted OR, 3.69; CI95,
1.27 to 10.78), and the number of antibiotics received
(adjusted OR, 1.46; CI95, 1.15 to 1.86) (Table 2). 
Treatment
Of the 113 patients identified with candidemia, 32
(28%) did not have a follow-up blood culture. Thirteen
(28%) of 47 patients surviving 14 days or longer received
less than 14 days of antifungal therapy. Of the 34 patients
receiving at least 14 days of therapy, only 17 (50%)
received 2 weeks of treatment beyond the last positive
blood culture. Of those receiving less than 14 days of
treatment, approximately half had only 1 positive blood
culture. Eight (10%) of the patients with at least 7 days in
the hospital received no antifungal treatment. 
Amphotericin B was the initial antifungal agent used
TABLE 1 (cont’d)
RISK FACTORS FOR CANDIDEMIA
All Species
No. of Case- No. of Control-
Factor Patients (%) Patients (%) OR CI95
Outcome
Mortality 29 (38.7) 3 (4.0) 15.8 4.55–55.02†
OR = odds ratio; CI95 = 95% confidence interval; APACHE = Acute Physiology and Chronic Health Evaluation; COPD = chronic obstructive pulmonary disease; ESLD = end-stage liver disease; CAD =
coronary artery disease; CHF = congestive heart failure; ICU = intensive care unit; PICC = peripherally inserted central catheter; RBC = red blood cell; ENT = ear, nose, and throat.
*Number of case-patients = 75; number of control-patients = 75.
†Significant at P < .05.
‡Kendall, Mansfield, MA.
TABLE 2
MATCHED (IE, PRINCIPAL DIAGNOSIS, AGE, AND LENGTH OF STAY)
CASE–CONTROL MULTIVARIATE ANALYSIS FOR PREDICTORS OF
CANDIDEMIA
Variable Unit Adjusted OR CI95
Hickman catheter Yes/no 9.53 1.34–68.01
Gastric acid suppressants Yes/no 6.38 2.33–17.43
ICU admission Yes/no 6.40 2.12–19.31
Nasogastric tube Yes/no 3.69 1.27–10.78
No. of antibiotics Continuous 1.46 1.15–1.86
OR = odds ratio; CI95 = 95% confidence interval; ICU = intensive care unit.
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in 32 (28%) of the case-patients. This was subsequently
switched to fluconazole in 18 (56%) of those patients.
Conversely, fluconazole was the initial antifungal in 61
(54%) of the 113 case-patients but was subsequently
switched to amphotericin in 24 (39%). Of the patients with
C. albicans, 8 (13%) received only amphotericin and 4
(50%) of these patients died, whereas 24 (38%) of the
patients received only fluconazole and 5 (21%) of these
patients died. Of the patients with C. glabrata, 2 (12%)
received only amphotericin and 1 (50%) patient died,
whereas 3 patients (18%) received only fluconazole and 2
(67%) of these patients died.
DISCUSSION
Over the years, many studies evaluating risk factors
for the development of nosocomial candidemia have been
conducted; however, most have been in specific patient
populations, have been generally retrospective, and have
not used a case–control methodology.12-18 Studies that
employed a case–control design were conducted prior to
the widespread use of azole antifungal agents. Using a
case–control design, we identified several independent
risk factors for the development of nosocomial can-
didemia including the presence of a Hickman catheter,
the presence of a nasogastric tube, ICU admission, and
receipt of multiple antibiotics. The results of this matched
case–control study confirm risk factors cited in other
studies, which, despite the widespread use of azole anti-
fungals, have not changed substantially over the years.
Interestingly, we also identified the use of gastric acid sup-
pressants as an independent risk factor. To the best of our
knowledge, this risk factor has not previously been docu-
mented. In critically ill patients, gastric alkalinization has
been associated with an increase in gastric bacterial and
fungal colonization.21-23 Several reports have also found a
role for gastric acid inhibitors as predisposing factors in
the development of Candida esophagitis.24,25 Although
gastric alkalinization may increase gastric bacterial and
fungal colonization, there are no data to suggest that an
increase in gastric colonization would lead to an increase
in bloodstream infections. Numerous studies have shown
that shock, parenteral nutrition, and antibiotics facilitate
the translocation of enteric bacteria.26-31 Gastric alkaliniza-
tion, with concomitant bacterial and fungal overgrowth, in
critically ill ICU patients receiving multiple antibiotics
may facilitate the translocation of Candida. Further stud-
ies will be necessary to confirm this finding. 
Although many studies have documented an
increase in the prevalence of non-albicans Candida species,
particularly C. glabrata,2,5,10,11,32 the number and distribu-
tion of Candida species recovered were similar to those
found in a retrospective case study evaluating predictors of
mortality19 performed at the same institution from 1988 to
1989. A greater percentage of patients had C. parapsilosis in
2000 (16%) compared with 1988 to 1989 (6.5%). However,
the percentages of patients identified with C. glabrata were
similar: 15% in 2000 versus 13% (14 of 106) in 1988 to 1989.
In addition, we did not find a statistically significant
difference in the percentage of isolates identified as C.
albicans, C. tropicalis, or C. krusei. 
C. parapsilosis, as a cause of fungemia, has been
identified most recently in 7% of patients enrolled in both
a statewide, longitudinal surveillance study of candidemia
and the National Epidemiology of Mycoses Survey
(NEMIS) study among surgical ICU patients.9,32 Other
studies including the SCOPE project have identified C.
parapsilosis in 4% to 11% of patients with fungemia.2,4 By
contrast, C. parapsilosis was the etiologic agent of can-
didemia in 29% of neonatal ICU patients in the NEMIS
study.9 Historically, C. parapsilosis has accounted for 3% to
27% of cases of fungemia in large hospital-based studies.33
During a 12-year period from 1983 to 1994, the frequency
of C. parapsilosis fungemia increased from 8% to 30%
among patients with hematologic malignancies.34 In stud-
ies showing an increase in non-albicans candidemia over
time, C. glabrata accounted for the increase. The increase
in C. parapsilosis in the current study may be related to
geographic variations. 
Recent practice guidelines of the Infectious Diseases
Society of America for the treatment of candidemia recom-
mend the continuation of therapy for 2 weeks after the last
positive blood culture and resolution of signs and symp-
toms of infection.35 Given the design of our study, we did
not find significant differences in mortality based on the
duration of therapy or length of time to documented nega-
tive blood cultures. Previous studies have documented
unacceptably high mortality rates in untreated patients.
However, there remains a small subset of patients who
rapidly clear their candidemia (within 24 hours), are less
acutely ill, and have shorter hospital stays who survive
inadequate antifungal therapy.19 Treating these carefully
selected patients with a short course of amphotericin B has
proved successful.36 The substantial number of patients in
our study not receiving adequate therapy based on estab-
lished guidelines suggests that additional educational
efforts regarding therapy should be directed toward physi-
cians caring for these patients. In addition, further prospec-
tive studies are needed to determine the appropriate dura-
tion of therapy based on risk factors as well as to evaluate
the impact on late complications. 
Although there may be regional differences in per-
centages of Candida isolates causing disease, the major
identified risk factors and crude mortality of candidemia
have not significantly changed during the past several
decades despite the availability of azoles. This study was
performed before the availability of echinocandins that
may enhance the effectiveness of candidemia therapy. It is
also apparent that many patients do not receive adequate
therapy based on current Infectious Diseases Society of
America guidelines. Prospective, well-controlled studies
among carefully selected patients are needed to evaluate
the appropriate duration of therapy. Similarly, given the
increased and unchanging mortality of candidemia, stud-
ies to evaluate the benefits of preventive therapy are
essential if we are to have any impact on the outcome of
this infection. 
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